Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor-alpha; therapy: Is there a need for more comprehensive screening procedures?
Arthritis Care and Research , 06/03/09
Nannini C et al. – The results of randomized controlled trials (RCTs) show that 26% of malignancies occur within 12 weeks from enrollment in patients receiving anti-TNF therapies suggesting the need for a revision of current cancer screening procedures in RCTs and in clinical practice.
Methods- A systematic review to monitor the occurrence of malignancies among pts with RA, psoriatic arthritis (PsA), and ankylosing spondylitis (AS) treated with anti-TNF therapy
- Primary outcome: report of frequency of malignancies in RCTs and the latency between the therapy introduction and the occurrence of the neoplasm
- 363 consecutive RA, PsA, and AS pts requiring anti-TNF therapy from 2002 to 2006, underwent extensive cancer screening procedures
- An historical controlled group of 73 pts treated between Jan 1999 and Dec 2001 underwent the screening procedures accepted for the RCT procedures
- 36 RCTs; malignancies occurred in 60/8,015 (0.75%) pts randomized to the active treatment arm and in 21/3,991 (0.52%) pts in the placebo arms
- In the personal retrospective case series, 0.27% pts and 4.1% controls developed cancer over the f/u period
- Mean ± SD f/u duration was 40.9 ± 16.7 mo in study pts and 50.6 ± 18.1 mo in controls
Today in Other Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis
Rheumatology International, 10/26/09
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
Annals of Rheumatic Diseases, 10/12/09
The beneficial effects of a 3 week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: Results of the STIVEA trial
Annals of Rheumatic Diseases, 10/23/09
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study
Arthritis Care and Research , 11/03/09
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09
Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up
Scandinavian Journal of Rheumatology , 09/28/09
Today in Spondylarthropathies...keeping you current
Receive free subspecialty "5-minute updates" via email
Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years drug survival
Rheumatology International, 10/14/09
Erythrocyte sedimentation rate, CRP level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis
Arthritis Care and Research , 11/02/09
Recreational Exercise in Rheumatic Diseases
International Journal of Sports Medicine, 10/30/09
Sponsor
Article Search
Sponsor


See Latest Articles


